Matthew Harrison, DO
Family Medicine · Louisville, KYNPI 1811489230
Payments from drug & device makers
Across 288 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$573
- Pfizer$429
- AstraZeneca$305
- Lilly USA, LLC$209
- Idorsia Pharmaceuticals US Inc$180
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,277100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 119 | $1,295 |
| Novo Nordisk | 38 | $573 |
| Pfizer | 30 | $429 |
| AstraZeneca | 7 | $305 |
| Lilly USA, LLC | 13 | $209 |
| Idorsia Pharmaceuticals US Inc | 5 | $180 |
| Boehringer Ingelheim | 11 | $153 |
| Amgen | 9 | $132 |
| GSK | 7 | $107 |
| Novartis | 6 | $97 |
| Exact Sciences | 6 | $93 |
| Vanda Pharmaceuticals Inc. | 3 | $79 |
| Medtronic | 3 | $78 |
| Sumitomo Pharma America, Inc. | 3 | $62 |
| Merck | 3 | $60 |
| Bayer | 4 | $60 |
| Amarin Pharma, Inc. | 3 | $46 |
| Abbott | 3 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Abiomed | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Vertex | 1 | $23 |
| Johnson & Johnson | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Smith+Nephew | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,280 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 110 | $126,950 |
| OzempicSemaglutide | 94 | $104,922 |
| JardianceEmpagliflozin | 74 | $90,597 |
| FarxigaDapagliflozin Propanediol | 90 | $77,481 |
| JanuviaSitagliptin Phosphate | 41 | $58,202 |
| RybelsusSemaglutide | 34 | $45,427 |
| MounjaroTirzepatide | 35 | $38,238 |
| TrulicityDulaglutide | 15 | $31,413 |
| GemtesaVibegron | 35 | $28,211 |
| XareltoRivaroxaban | 21 | $27,665 |
| EntrestoSacubitril/Valsartan | 27 | $24,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $20,121 |
| MyrbetriqMirabegron | 17 | $16,496 |
| Repatha SureclickEvolocumab | 19 | $14,894 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $11,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $573 | $150,348128 claims |
| PfizerEliquis | $429 | $126,950110 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $153 | $101,86090 claims |
| AstraZenecaFarxiga | $305 | $77,48190 claims |
| Lilly USA, LLCMounjaro, Trulicity | $209 | $69,65150 claims |
| MerckJanuvia, Janumet | $60 | $67,48452 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $107 | $36,00662 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $62 | $28,21135 claims |
| Johnson & JohnsonXarelto | $17 | $27,66521 claims |
| NovartisEntresto | $97 | $24,82027 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $16,49617 claims |
| AbbVieSynthroid | $1,295 | $2,59656 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Louisville
- Christopher RhyneLouisville$1M
- Michael LovelaceLouisville$244K
- Suraj GathaniLouisville$69K
- Mandy WhittLouisville$38K
- Michael PendletonLouisville$29K
- Rajanbhai AminLouisville$26K
- James WrightLouisville$18K
- Rosenberg ReyesLouisville$18K
- Dennis GrayLouisville$14K
- Vincent LangLouisville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.